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ABSTRACT 
Over 100,000 cases of COVID-19 patients infected 
with the novel corona virus SARS-COV-2 have been 
reported worldwide in approximately 2 months, 
resulting in over 3000 deaths. Potential therapeutic 
strategies, including remdesivir, chloroquine 
phosphate, abidol, lopinavir/ritonavir, plasma, 
antibody, vaccine and stem cells are discussed in this 
review. With the number of patients increasing 
daily, there is an urgent need for effective 
therapeutic intervention. 
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1. Introduction 
 
Since the beginning of December 2019, numerous 
hospitals in Wuhan, China have reported an 
increasing number of patients with pneumonia due 
to the infection with an unknown virus. The virus, 
first named 2019 novel Corona Virus (2019-nCoV), 
was later changed to Severe Acute Respiratory 
Syndrome Corona Virus 2 (SARS-COV-2), and the 
pneumonia was named Corona Virus Disease 2019 
(COVID-19). World Health Organization (WHO) 
declared COVID-19 a Public Health Emergency of 
International Concern on January 31, and, as of 
March 2020, the virus has infected >90,000 people, 
and killed >3,100 worldwide1. With the number of 
patients increasing daily, there is an urgent need for 
effective therapeutic intervention. In this article, we 
will discuss several therapeutic strategies against 
COVID-19 infection. 
 
2. Nucleotide analogs 
 
The first case of COVID-19 in the United States was 
confirmed on January 20, 2020, by qPCR assay with 
samples from the patient’s nasopharyngeal and 
oropharyngeal swabs. Probes were based on 
genomic sequence of 2019-nCoV released by 
scientists from China. After the development of 
radiographic pneumonia, the patient was treated with 
remdesivir intravenously and almost all clinical 
symptoms resolved the following day2. Remdesivir 
(Figure 1) is a nucleotide analog originally 
developed by Gilead as a drug against Ebola virus. 
Mechanistically, it inhibits RNA-dependent RNA 
synthetase (RdRp) with completed Phase I and/or II 
clinical trials3,4. Therefore, Gilead has been working 
with China since February 2020 to conduct a phase 3 
randomized, double-blinded, placebo-controlled, 
multicenter trial to determine the safety and efficacy 
of remdesivir on hospitalized patients with severe 
COVID-195. The treatment was designed as 200 mg 
of remdesivir on day 1 followed by 100 mg/day for 
9 days. The study is expected to be completed by 
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May 1, 20206. In addition, other antiviral nucleotide 
analogs such as fapivir and ribavirin are undergoing 
clinical trials. Fapivir is a drug approved in Japan for 
flu treatment. 
 
3. Chloroquine phosphate 
 
Chloroquine phosphate is an antimalarial drug. By 
increasing the pH of the nucleus, it can inhibit both 
the virus-host cell interaction and the pH-dependent 
virus replication7. The results from in vitro studies 
suggest that chloroquine can actively inhibit SARS-
COV-24. Both animal experiments and clinical trials 
are currently in progress. Results from preliminary 
clinical trials show that chloroquine phosphate has 
promising effects on patients with COVID-19. Of 
note, it has been reported that chloroquine may 
cause adverse reactions such as ocular disorders, 
immune system disorders, ear and labyrinth 
disorders, cardiac disorders, etc.8, therefore 
precautions and further testing are needed for the 
safe and effective treatment in COVID-19 patients. 
 
4. Abidol 
 
Abidol is a broad-spectrum antiviral drug. By 
inhibiting the fusion between the influenza virus and 
host cells, it can inhibit virus replication. It has been 
used to prevent/treat both SARS and Middle East 
Respiratory Syndrome (MERS). According to an 
online report, Abidol in the concentration range of 
10-30μM not only inhibited COVID-19 duplication, 
it also significantly reduced the pathological effect 
of the virus9. A randomized multi-center controlled 
clinical trial wtih Abidol in patients with COVID-19 
has started in Xiangya Hospital in China, which has 
been registered in the US clinical trial database10. 
 
5. Lopinavir/ritonavir  
 
Lopinavir/ritonavir is a combination of drugs mainly 
used for AIDS treatment. Lopinavir inhibits viral 
protease resulting in immature/non-infectious virus 
particles; ritonavir inhibits the degradation of 
lopinavir in the liver and thereby extends lopinavir’s 
half-life. Results from in vitro studies showed that 
lopinavir/ritonavir can inhibit the replication of both 
MERS and SARS11. However, whether they can 
inhibit COVID-19 is unknown. Therefore, a clinical 
trial to use lopinavir/ritonavir for COVID-19 
treatment will be launched soon in a hospital in 
Wuhan, China. In addition, since darunavir (trade 
name: Prozekal) is another protease inhibitor used 
for HIV treatment, a combination of darunavir and 
ritonavir could also be a potential treatment of 
COVID-19, especially since darunavir has been 
approved in China since 2018 for HIV treatment. 
 
6. Plasma 
 
The company CNBG claimed on February 13, 2020, 
that plasma from recovered patients was used to 
successfully cure 11 critically ill patients with 
COVID-1912. The donated plasma with high-titer of 
 
 
 
 
Figure 1. The structure of remdesivir, a nucleoside analog with antiviral activity. 
Results from experiments conducted on Vero E6 cells indicate that the EC90 for SARS-COV-2 is 1.76μM4. 
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     KEY POINTS 
◊ The recent COVID-19 disease is due to the infection with the new coronavirus, SARS-
CoV-2, causing a pandemic and necessitates the development of effective 
therapeutics. 
◊ Many clinical trials are initiated worldwide. Potential therapeutics, including 
nucleotide analogs，chloroquine phosphate，abidol，lopinavir/ritonavir，plasma 
antibodies，vaccines, stem cells are among the most important strategies to be 
developed. 
SARS-COV-2 antibodies was confirmed without 
pathogens and with virus inactivation12. Of note, 12 
to 24 hours post-treatment, the major inflammation 
symptoms decreased significantly with increased 
lymphocytes counts and blood oxygen saturation. 
Improved vital signs were also observed. Currently, 
although the exact underlying mechanisms are 
unknown, it is reasonable to speculate that the 
antibodies may bind the virus and prevent virus-host 
cell interaction, and therefore prevent infection. In 
addition, NK cells and other immune cells may also 
be involved in clearing the virus by antibody-
dependent cell-mediated cytotoxicity. However, the 
potential risks associated with plasma usage, 
including pathogen transmission and allergic 
reaction, should be considered, and therefore this 
strategy may only be applied for a clinical 
emergency following standardized procedures. On 
the other hand, specific immunoglobulin could be a 
better option for treating critically ill patients with 
SARS-COV-2 infection. 
 
7. Antibodies 
 
Specific neutralizing antibodies against viral surface 
proteins may bind and prevent the virus from 
entering the host epithelial cells and subsequently 
prevent virus amplification. On the other hand, non-
neutralizing antibodies may bind the virus and 
activate the immune cells (mainly macrophages) to 
engulf and clear the virus. However, excessive 
activation of these non-specific immune cells may 
cause the release of a large number of pro-
inflammatory factors leading to cytokine storm and 
sepsis-related death. Therefore, non-neutralizing 
antibodies play an antiviral role in the early stages 
but may cause lung damage at later stages. However, 
it usually takes an extended period of time to 
generate monoclonal antibodies for a new pathogen 
that can be used clinically. 
Regeneron Pharmaceuticals is using 
VelociSuite technology with a humanized mouse 
immune system to rapidly develop innovative 
antibodies for the treatment of virus sepsis. This 
strategy has shown positive results in clinical trials 
using antibodies to treat Ebola13. The German 
company Inflarx has developed a monoclonal 
antibody against the human C5a molecule. By 
specifically binding and inhibiting C5a-mediated 
biological functions, including the release of 
neutrophil chemotaxis and intra-cellular lysozyme, 
the antibodies can limit excessive inflammation 
without inhibiting immune function. Clinical trials 
on this antibody are now underway in China to 
potentially reduce both lung damage and death 
caused by sepsis infection14.  
 
8. Vaccines 
 
There are now at least four candidate vaccines 
against the sepsis that are under development. 
Clinical trials on the most promising vaccine 
candidates may start in three to four months. 
However, it usually takes more than a year for a 
vaccine to become clinically applicable15. 
 
9. Stem cells 
 
Due to the self-renewal and multi-directional 
differentiation capability of mesenchymal stem cells, 
they can be differentiated to produce multifunctional 
cells. In damaged lung tissues, stem cells may be 
able to replenish bronchial epithelial and endothelial 
cells after the clearance of viral infection. They may 
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also stabilize the pulmonary micro blood vessel and 
alveolar epithelial cell barriers. These effects could 
enhance the patient's immunity, alleviate pneumonia, 
and prevent secondary infections. As of February 14, 
2020, more than 4 such projects have been approved 
for the treatment of COVID-19 in China, and 
another one has applied to the U.S. Food and Drug 
Administration (FDA) for emergency approval16. 
 
10. Others 
 
Other clinical trials of treatment options are also on 
the agenda. A search with the word “COVID-19” in 
the China Clinical Trials Registry 
(http://www.chictr.org.cn) revealed that 218 clinical 
trials have been registered on the platform as of 
March 9. Dozens of clinical trials have also been 
registered on the international platform of clinical 
trials (https://clinicaltrials.gov/). Recently, as a key 
target for therapeutic intervention, the cryo-EM 
structure of the CoV spike protein in its trimer form 
has been elucidated, which may further contribute to 
therapeutic designs in the near future17.  
 
11. Conclusion 
 
Currently, remdesivir appears to be the most 
promising drug for the treatment of pneumonia 
caused by COVID-19 pneumonia. Many other 
agents or strategies are being tested for the treatment 
of patients with COVID-19. However, double-blind, 
randomized controlled trials are required to 
investigate their safety and efficacy. 
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